Our leadership team

European IPF Patient Summit
Steering Committee

Carlos Lines Millán

EU-IPFF President

Carlos Lines Millán was elected president of the European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF) in 2016. He is also co-founder and president of the Spanish IPF association AFEFPI (Asociación de familiares y enfermos de fibrosis pulmonar idiopática). Mr. Lines has been active in the health field, with a focus on IPF, over the past 10 years, leading on multiple initiatives at the local, national and EU levels.

Liam Galvin

EU-IPFF Secretary

In addition to representing the Irish Lung Fibrosis Association, Liam is one of the co-founders of EU-IPFF. He is on the European Lung Foundation Patient Advisory Committee, is a Patient Lead with the European Reference Network on Rare Respiratory Lung Diseases, has co-authored various publications including the joint ATS/ERS/ALAT/JTS guidelines on IPF Diagnosis in 2018, is a member of the ERS led Ariane IPF Meta-Registry project and is registered with the EMA as a patient expert. Liam focuses his advocacy work on promoting the collective working of academia, health care professionals, industry and patients.

Klaus Geissler

German Lungenribrose e.V Representative

Klaus is the representative to EU-IPFF from the German Lungenribrose e.V. In 2012, he was diagnosed with IPF and has since gathered information about the management of this disease and the patient advocacy landscape in Europe. He disseminates this information during speeches and written publications. He is also supporting HCPs with the development of national guidelines.

Steve Jones

Action for Pulmonary Fibrosis UK Representative

Steve Jones is the Chair of Action for Pulmonary Fibrosis, UK. He suffered from Idiopathic
Pulmonary Fibrosis for eight years but was fortunate to receive a lung transplant in 2016.
During his professional life, he worked as an adviser to the European Union, World Bank and other agencies on development programmes in Asia and Africa. He is a European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF) Executive Board Member and is a member of the Council of the European Lung Foundation.

Radostina Getova

Idiopathic Pulmonary Fibrosis Association Bulgaria Representative

Radostina is a communication consultant and has been working with rare disease patient groups for four years in the fields of policy, advocacy and social awareness. Her extensive experience in public relations and communications, with both national and international non-governmental organizations, has given her the knowledge and tools to develop the foreign activity and partnership relations of patient societies, such as the Idiopathic Pulmonary Fibrosis Association Bulgaria.

Piotr Radwan- Rohrenschef MD, PhD

IPF Polish Society Representative

Dr. Radwan-Röhrenschef has been working with pulmonology patients for over twenty years and has recently specialised in ILD and IPF patients. He is a pulmonologist, with a primary interest in diagnostic methods of ILD, particularly bronchoscopy and cryobiopsy. He is also the EU-IPFF Delegate from the Polish Society for Idiopathic Pulmonary Fibrosis Patients’ Support.

Katarzyna Lewandowska, MD, PhD

National Tuberculosis and Lung Diseases Research Institute Warsaw

Working with IPF and ILD patients for over 15 years, Dr. Lewandowska works in the largest ILD center in Poland. She is also a member of the working group preparing the first Polish IPF diagnosis and treatment guidelines, regularly holds lectures for students and doctors, as well as being active in research. Additionally, Dr. Lewandowska is a founder and Vice President of the Polish IPF Patients’ Society.

Assoc. Prof. Paolo Spagnolo

University of Padua, Italy

Dr. Spagnolo has been working in the field of interstitial lung diseases for almost 20 years, including six years at the Royal Brompton Hospital in London, where he was awarded a PhD in genetics of sarcoidosis. His main research interests are surrounding genetic predisposition to pulmonary fibrosis and the development of novel treatments. He has co-authored more than 100 peer-review publications, mostly around interstitial lung diseases, idiopathic pulmonary fibrosis and sarcoidosis.

Anne-Marie Russel

Imperial College London

Anne-Marie is a post-doctoral researcher at Imperial College Healthcare NHS Trust London. Her research interests are in patient centredness, health metrics and fibrotic lung conditions. Projects include exploring the usefulness of Patient Activation Measures in people; validating an Interstitial Lung Diseases (ILD) specific Patient Reported Experience Measure (PREM) and further validation and translation of the 12-item patient-reported outcome measure for patients with idiopathic pulmonary fibrosis (IPF-PRoM© 2018 Imperial Innovations). Anne-Marie represents ILD nursing interests at international committees including the EU-IPFF.

Francesco Bonella

Ruhrlandklinik Medical Faculty University of Duisburg-Essen

Francesco Bonella is Associate Professor of Medicine and Head of the Division for Interstitial and Rare Lung Disease, Department of Pneumology at the Ruhrlandklinik University Hospital in Essen, Germany. After receiving his MD and Board Certification at the University of Verona, Italy, he earned his international PhD in Interstitial Lung Diseases at the University of Essen under the guidance of Professor Ulrich Costabel. Dr Bonella’s research interests include IPF, alveolar proteinosis, rheumatic-associated ILDs, and sarcoidosis with a special focus on biomarkers, genetic predisposition and applications of bronchoalveolar lavage. In recent years, he has acted as an investigator for major clinical trials in IPF, sarcoidosis and alveolar proteinosis. He is a reviewer for numerous scientific journals, Section Editor of Current Opinion in Pulmonary Medicine and has authored many chapters in textbooks, original articles, case reports, editorials and reviews. He is the Chair of the ERS Rare DPLD Group (12.04) and co-founded EuPAPNet, the European Network for pulmonary alveolar proteinosis. He is also the Head of the Scientific Advisory Board of European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EUIPFF).

Antje Prasse

Hannover Medical School

Prof. Dr. Michael Kreuter

Thoraxklinik - Universitätsklinikum Heidelberg

Dr. Kreuter is a Professor of Internal Medicine at the University of Heidelberg, Germany, as well as Head of the Centre for Interstitial and Rare Lung Diseases, Thoraxklinik, University of Heidelberg, which is a European Reference network (ERN) certified ILD centre. Furthermore, he is a principal investigator of the German Centre for Lung research. Dr. Kreuter is board certified in internal medicine, pulmonology and haematology-oncology. Following a clinical fellowship in Münster, Germany and a research fellowship at Harvard Medical School Boston, USA, he has been working at the Thoraxklinik since 2005. His clinical and scientific interests focus on interstitial and rare lung diseases. He is conducting a number of research projects on comorbidities, epidemiology, biomarkers and diagnosis and therapy of interstitial lung diseases. He is also committed to educational programmes and will host the ERS ILD school in November 2019 and April 2020.

Claudia Valenzuela

Hospital La Princesa Comunidad de Madrid

Assoc. Prof. Wim Wuyts

Catholic University of Leuven

Dr. Wuyts is the Associate Professor at the Catholic University of Leuven (K U Leuven), Belgium, where he is Head of the Laboratory of Respiratory Medicine and the driving force behind the interstitial lung disease programme. He is also Head of the Unit for Interstitial Lung Diseases and is involved in the Unit of Pulmonary Hypertension at University Hospitals Leuven. His speciality is in interstitial lung disease and pulmonary arterial hypertension. His research interests include chronic inflammation and fibrosis and he conducts clinical research in interstitial lung disease. Furthermore, Dr. Wuyts is a member of various national and international taskforces and scientific boards, in addition to being elected as a member of the Executive Committee of the World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) in October 2014.